Journal of Nephrology

, Volume 28, Issue 2, pp 187–191 | Cite as

Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage

  • Giuseppe Rombolà
  • Franco Vaira
  • Matteo Trezzi
  • Nadia Chiappini
  • Valeria Falqui
  • Francesco Londrino
Original Article

Abstract

Background

Pemetrexed (Alimta®) (PEM) is an antifolate antineoplastic agent effective in several tumor types, such as non-small-cell lung cancer (NSCLC) and mesothelioma, among others. It is almost exclusively excreted by the kidney and an eGFR lower 45 mL/min is a contraindication for its use: above this level PEM administration is considered safe and dose adjustment is not required. Although there are some reported cases of PEM-induced renal injury, its incidence and the negative effects on patients’ outcome has not been systematically evaluated.

Methods

We report a retrospective evaluation on the incidence of PEM-induced renal injury in patients affected by NSCLC. Between June 2010 and March 2012 a total of 38 NSCLC patients were treated at our hospital. In 29 of them other possible cause of renal injury were excluded and thus they were eligible to be analysed.

Results

Although by protocol all of them had eGFR >45 mL/min at baseline, six patients (average eGFR 56.2 ± 11.5 mL/min/1.73 m2) developed AKI (21 %). In these six patients PEM-induced myelosuppression was more severe and hospitalization was longer. Kidney function completely recovered in four patients whereas in the other two deterioration of renal function was irreversible. The number of patients with baseline eGFR <60 mL/min/1.73 m2 was higher (4/6) in the group that developed AKI as compared to those who did not (6/23) (p < 0.05).

Conclusions

There is no clear cut eGFR above which PEM may be used without potential risks of renal toxicity. If PEM has to be used, all the coexisting risk factors for AKI should be possibly corrected.

Keywords

Acute kidney injury Bone marrow toxicity Not small cell lung cancer Pemetrexed 

References

  1. 1.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644CrossRefPubMedGoogle Scholar
  2. 2.
    Santoro A, O’Brien ME, Stahe RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom L, Liu Y, Ripoche V, Blatter J, Visseren-Gru CM, Manegold C (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaıve patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol 3(7):756–763CrossRefPubMedGoogle Scholar
  3. 3.
    Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller T, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M (2013) A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 14(3):215–223CrossRefPubMedGoogle Scholar
  4. 4.
    Socinski MA, Stinchcombe TE, Hayes DN (2005) The evolving role of pemetrexed (Alimta) in lung cancer. Semin Oncol 32(2 Suppl 2):16–22 (Review)CrossRefGoogle Scholar
  5. 5.
    Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432–1440CrossRefPubMedGoogle Scholar
  6. 6.
    Grønberg BH, Bremnes RM, Fløtten O et al (2009) Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27(19):3217–3224CrossRefPubMedGoogle Scholar
  7. 7.
    Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589–1597CrossRefPubMedGoogle Scholar
  8. 8.
  9. 9.
    http://www.uptodate.com. Accessed 27 Feb 2014
  10. 10.
    Levin A, Warnock DG, Mehta RL et al (2007) Improving outcomes from acute kidney injury: report of an initiative. Am J Kidney Dis 50:1–4CrossRefPubMedGoogle Scholar
  11. 11.
    Jassem J, Ramlau R, Santoro A et al (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26(10):1698–1704CrossRefPubMedGoogle Scholar
  12. 12.
  13. 13.
  14. 14.
    Paz-Ares LG, De Marinis F, Dediu M et al (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31:2895–2902CrossRefPubMedGoogle Scholar
  15. 15.
    Glezerman IG, Pietanza MC, Miller V, Seshan SV (2011) Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis 58(5):817–820CrossRefPubMedGoogle Scholar
  16. 16.
    Vootukuru V, Liew YP, Nally JV Jr (2006) Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol 23:419–422CrossRefPubMedGoogle Scholar
  17. 17.
    Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H (2009) Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol 2:53–56CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Stavroulopoulos A, Nakopoulou L, Xydakis AM, Aresti V, Nikolakopoulou A, Klouvas G (2010) Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail 32:1000–1004CrossRefPubMedGoogle Scholar
  19. 19.
    Porta JM, Vicente de Vera Floristán C, Inglán PB, Jericó JF (2009) Acute renal failure associated with Pemetrexed (Alimta®). Nefrologia 29:610–611PubMedGoogle Scholar
  20. 20.
    Chauvet S, Courbebaisse M, Ronco P, Plaisier E. Pemetrexed-induced acute kidney injury leadind to chronic kidney disease. Clin Nephrol. 2014 (Epub ahead of print)Google Scholar
  21. 21.
    Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity. Kidney Int 74:1385–1393CrossRefPubMedGoogle Scholar
  22. 22.
    Bodmer M, Amico P, Mihatsch MJ et al (2007) Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant 22:2366–2370CrossRefPubMedGoogle Scholar
  23. 23.
    Barri YM, Munshi NC, Sukumalchantra S et al (2004) Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65:634–641CrossRefPubMedGoogle Scholar
  24. 24.
    Markowitz GS, Appel GB, Fine PL et al (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12:1164–1172PubMedGoogle Scholar
  25. 25.
    Desikan R, Veksler Y, Raza S et al (2002) Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 119:496–499CrossRefPubMedGoogle Scholar
  26. 26.
    McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf. 13:228–244CrossRefPubMedGoogle Scholar
  27. 27.
    Hannemann J, Baumann K (1990) Nephrotoxicity of cisplatin, carboplatin and transplatin. Arch Toxicol 64:339–400CrossRefGoogle Scholar

Copyright information

© Italian Society of Nephrology 2014

Authors and Affiliations

  • Giuseppe Rombolà
    • 1
    • 3
  • Franco Vaira
    • 2
  • Matteo Trezzi
    • 1
  • Nadia Chiappini
    • 1
  • Valeria Falqui
    • 1
  • Francesco Londrino
    • 1
  1. 1.Nephrology and Dialysis UnitSt. Andrea HospitalLa SpeziaItaly
  2. 2.Oncology UnitSt. Andrea HospitalLa SpeziaItaly
  3. 3.Nephrology Dialysis and Kidney TransplantMacchi Foundation HospitalVareseItaly

Personalised recommendations